GSK (GSK) News Today GBX 1,354 -9.26 (-0.68%) As of 12:44 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainability All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period GSK gets EU nod for expanded use of Jemperli in endometrial cancerJanuary 20 at 4:59 AM | lse.co.ukGSK rises Friday, still underperforms marketJanuary 17 at 4:09 PM | marketwatch.comBrokerages Set GSK plc (LON:GSK) Price Target at GBX 1,805.83GSK plc (LON:GSK - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five haveJanuary 17 at 4:11 AM | marketbeat.comJ.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK)January 16, 2025 | markets.businessinsider.comGSK To Acquire GIST Drug Developer IDRx For Up To $1.15 Bln CashJanuary 14, 2025 | markets.businessinsider.comGSK To Buy US-Based Stomach Cancer Drug Developer For Over $1 BillionJanuary 14, 2025 | benzinga.comGSK plc (LON:GSK) Receives Average Rating of "Moderate Buy" from BrokeragesJanuary 14, 2025 | americanbankingnews.comGSK plc (LON:GSK) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of GSK plc (LON:GSK - Get Free Report) have been given an average recommendation of "Moderate Buy" by the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold raJanuary 14, 2025 | marketbeat.comGSK CEO on US Expansion, M&A, Drug Pipeline, TrumpJanuary 13, 2025 | finance.yahoo.comGSK CEO Optimistic About Dealmaking, New Trump AdministrationJanuary 13, 2025 | msn.comGSK to buy Boston-based IDRx for $1.15 billionJanuary 13, 2025 | msn.comGSK, Pfizer RSV vaccines to carry warnings of GBS, Reuters reportsJanuary 8, 2025 | markets.businessinsider.comGSK Nears $1 Billion Deal for Biotech Company IDRxJanuary 8, 2025 | msn.comGSK (LON:GSK) Earns Underweight Rating from JPMorgan Chase & Co.JPMorgan Chase & Co. reissued an "underweight" rating on shares of GSK in a research note on Tuesday.January 7, 2025 | marketbeat.comWhy Is GSK plc (NYSE:GSK) Among the Best FTSE Dividend Stocks to Buy Now?January 6, 2025 | msn.comGSK treatment approved for adults with sinus condition in ChinaJanuary 3, 2025 | lse.co.ukGSK's Sinus Disease Drug Secures Approval In ChinaJanuary 3, 2025 | finance.yahoo.comGSK’s Nucala approved in China as add-on therapy for adults with CRSwNPJanuary 3, 2025 | msn.comGSK gets approval in China for Nucala for rhinosinusitisJanuary 3, 2025 | msn.comGSK (LON:GSK) Share Price Passes Below Two Hundred Day Moving Average - What's Next?GSK (LON:GSK) Stock Crosses Below 200 Day Moving Average - Should You Sell?December 31, 2024 | marketbeat.comGSK plc (LON:GSK) Insider Jonathan Symonds Buys 1,500 SharesDecember 24, 2024 | insidertrades.comGSK plc (LON:GSK) Insider Jonathan Symonds Acquires 1,500 SharesGSK plc (LON:GSK - Get Free Report) insider Jonathan Symonds bought 1,500 shares of the firm's stock in a transaction that occurred on Friday, December 20th. The shares were acquired at an average cost of GBX 1,315 ($16.53) per share, with a total value of £19,725 ($24,792.61).December 23, 2024 | marketbeat.comGSK plc (LON:GSK) Given Consensus Rating of "Moderate Buy" by AnalystsGSK plc (LON:GSK - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy ratingDecember 20, 2024 | marketbeat.comCorrection: GSK subsidiary ViiV Healthcare and Colombian regulatorsDecember 18, 2024 | ft.comGSK’s Cancer Drug Jemperli Nears EU Marketing ExpansionDecember 17, 2024 | msn.comGSK’s lung cancer therapy gains EMA PRIME designationDecember 17, 2024 | finance.yahoo.comGSK announces EMA granted PRIME Designation for GSK5764227December 16, 2024 | markets.businessinsider.com‘I’m not trying to turn GSK into Google’: How GSK’s Silicon Valley veteran has transformed the pharma giant into a tech powerhouseDecember 16, 2024 | msn.comGoldman Sachs Sticks to Its Hold Rating for GlaxoSmithKline (GSK)December 11, 2024 | markets.businessinsider.comGSK Is Doing The Right Things But Can't Catch A Break - Rating DowngradeDecember 11, 2024 | seekingalpha.comRelation-GSK to drive fibrotic and osteoarthritis developmentsDecember 11, 2024 | finance.yahoo.comJPMorgan Chase & Co. Reaffirms "Underweight" Rating for GSK (LON:GSK)JPMorgan Chase & Co. reiterated an "underweight" rating on shares of GSK in a report on Wednesday.December 11, 2024 | marketbeat.comRgenta Therapeutics Announces Strategic Alliance with GSK to Develop RNA-Targeted Small Molecule Splice ModulatorsDecember 4, 2024 | finance.yahoo.comBerenberg Bank Sticks to Its Buy Rating for GlaxoSmithKline (GSK)December 2, 2024 | markets.businessinsider.comGSK: Liquid Meningitis Vaccine Authorised in EUNovember 27, 2024 | marketwatch.comGSK eyes up combo approval for previously withdrawn myeloma drugNovember 25, 2024 | finance.yahoo.comGSK gains approval in Japan for extended indication of RSV vaccineNovember 25, 2024 | finance.yahoo.comGSK's Blenrep combinations accepted for review by US FDANovember 25, 2024 | lse.co.ukGSK :FDA Accepts Blenrep Combination For Review In Treatment Of Relapsed/Refractory Multiple MyelomaNovember 25, 2024 | markets.businessinsider.comGSK plc (LON:GSK) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of GSK plc (LON:GSK - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven analysts that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five haNovember 25, 2024 | marketbeat.comGSK announces Japan’s MHLW approved application to extend indication of ArexvyNovember 23, 2024 | markets.businessinsider.comTOP NEWS: GSK's Arexvy RSV vaccine approved in Japan for adults 50-59November 22, 2024 | lse.co.ukLONDON BRIEFING: GSK approval; Games Workshop trades ahead of forecastNovember 22, 2024 | lse.co.ukGSK Plc Announces Regulatory Expansion For Arexvy In Japan To Include Adults Aged 50-59November 22, 2024 | markets.businessinsider.comGSK announces phase III trial of linerixibat met primary endpointNovember 20, 2024 | markets.businessinsider.comDown 28%! What’s going on with GSK’s share price?November 20, 2024 | uk.finance.yahoo.comGSK reports positive Phase 3 results for linerixibat in PBC itchingNovember 19, 2024 | msn.comGSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some PatientsNovember 19, 2024 | finance.yahoo.comFTSE 100 Live 15 November: GDP disappoints, fresh GSK slump offsets Land Securities upgradeNovember 16, 2024 | msn.comGSK reports positive outcomes from Phase III multiple myeloma treatment trialNovember 16, 2024 | msn.com Get GSK News Delivered to You Automatically Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address GSK Media Mentions By Week GSK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GSK News Sentiment▼0.010.45▲Average Medical News Sentiment GSK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GSK Articles This Week▼95▲GSK Articles Average Week Get GSK News Delivered to You Automatically Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AZN News Today ITH News Today HCM News Today GRI News Today INDV News Today BMY News Today GPH News Today IGC News Today ARTL News Today PHAR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:GSK) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GSK plc Please log in to your account or sign up in order to add this asset to your watchlist. Share GSK With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
